![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CEPHALON DROPS ON SPARLON FDA REJECTION
CEPHALON DROPS ON SPARLON FDA REJECTION
August 10, 2006
Drug maker Cephalon Inc. said it will end development of a troubled attention deficit disorder treatment after receiving notification from the Food and Drug Administration that it could not approve the drug.
Yahoo Finance
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct